Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 457-460

  McDougall, David A J ^a   Morton, Anthony P ^a   Geoffrey Playford, E ^a,b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Microbiology Department   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antimicrobial resistance epidemiology; Quasi experimental studies; Statistical models

Indexed keywords

CARBAPENEM; ERTAPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHARMACY; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CARBAPENEMS; DRUG UTILIZATION; HOSPITALS; HUMANS; PSEUDOMONAS AERUGINOSA; QUEENSLAND;

EID: 84872382671     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks385     Document Type: Article

References (13)

1. Therapeutic Goods Administration. Australian Register of Therapeutic Goods. https://www.ebs.tga.gov.au/(8 August 2012, date last accessed).
2. Lee NY, Huang WH, Tsui KC et al. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011; 70: 150-3.
3. Frasca D, Marchand S, Petitpas F et al. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob Agents Chemother 2010; 54: 924-6.
4. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55: 306-11.
5. Goff DA, Mangino JE. Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem. J Infect 2008; 57: 123-7.
6. Goldstein EJ, Citron DM, Peraino V et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 5122-6.
7. Eagye KJ, Nicolau DP. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. J Antimicrob Chemother 2011; 66: 1392-5.
8. Office of Economic and Statistical Research. Queensland Population Update No. 16. 2010. http://www.oesr.qld.gov.au/products/publications/qld-pop-update/qld-pop-update-16.pdf (9 August 2012, date last accessed).
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Information Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
10. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-41.
11. Hay JL, Pettitt AN. Bayesian analysis of a time series of counts with covariates: an application to the control of an infectious disease. Biostatistics 2001; 2: 433-44.
12. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31: 485-90.
13. Lima AL, Oliveira PR, Paula AP et al. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009; 30: 487-90